As drug pipelines among major pharmaceutical manufacturers have become less productive, many companies have increasingly sought to establish a variety of partnering arrangements such as strategic alliances and joint ventures with small, innovative biotech companies as a source for new products. Further, the high cost of R&D, risk management considerations as well as market demand, makes it increasingly attractive for industry players to form alliances, often in the form of licensing or co-marketing/co-promotion agreements. The resulting benefits of these alliances include:
In short, we help provide licensors, and their investors, the confidence that they are maximizing the value of their intellectual property and the resulting cash flows from their licensing agreements. Our proactive approach to licensing management can also help pharmaceutical companies improve future agreement terms and build stronger relationships between business partners. By taking a proactive approach to licensing management, licensors can be confident that they are receiving accurate and complete royalty income and licensees can be confident that they are not paying more than they should.